The peptide world is thick with hype. Here’s how to read the actual research, understand what our reliability scores mean, and spot a source you shouldn’t trust.
PubMed is the free database of peer-reviewed biomedical literature. Search a peptide name (e.g. “BPC-157”), sort by newest, and read abstracts first. The abstract tells you the study design (animal vs. human, sample size) and the headline finding — enough to judge whether the claim is preliminary or established.
On this site, every claim links to its source via the ↗ source button. Click through and verify it yourself — that’s the whole point.
Every source is sorted into a tier, and every claim inherits a score (0–100) from that tier plus corroboration. Scores are capped at the source’s ceiling — a marketing page can never earn a 95, no matter how the copy reads. These are the tiers, highest to lowest:
Most peptides are Preclinical — the research is in rats or in vitro, not confirmed human trials. That’s legitimate signal (it tells you what scientists are studying), but it is not proof the peptide does the same thing in people. A few (semaglutide, tirzepatide) are Approved medicines with large human trials behind them. The research-status badge on each peptide page tells you which is which.
Now that you can read a source, learn how stacks work, or browse peptides by goal.